Vir Biotechnology Phase 2 Peninsula Trial Evaluating Vir-2482 For Prevention Of Symptomatic Influenza A Illness Did Not Meet Primary/Secondary Efficacy Endpoints
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology's Phase 2 Peninsula trial for Vir-2482, aimed at preventing symptomatic influenza A illness, did not meet its primary and secondary efficacy endpoints.
July 20, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vir Biotechnology's stock may be negatively impacted as their Phase 2 trial for Vir-2482 did not meet its primary and secondary efficacy endpoints.
Clinical trial results are a major driver of biotech stock prices. The failure of Vir Biotechnology's Phase 2 trial for Vir-2482 to meet its primary and secondary efficacy endpoints is a significant setback, which could negatively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100